Dualitas Therapeutics, Inc.

Based in the US, Dualitas Therapeutics focuses on developing advanced bispecific antibody therapies utilizing its DualScreen™ technology to tackle autoimmune and allergic diseases. Dualitas Therapeutics was founded in 2023 in San Francisco, US, specializing in innovative bispecific antibody therapies. The company raised USD 65. 00 mn in SERIES A funding on September 16, 2025, with key investors including Alexandria Venture Investments, Chugai Venture Fund, Eli Lilly & Company, Qiming Venture Partners, SV Health Investors, and Versant Ventures.

The founder's prior history is not publicly available. Dualitas Therapeutics specializes in the development of innovative bispecific antibody (BsAb) therapies through its proprietary DualScreen™ Bispecific Discovery Engine. This platform operates at a combinatorial scale, allowing the identification of unique co-target combinations that harness novel cell-surface proximity mechanisms for therapeutic applications. The company’s lead programs, DTX-102 and DTX-103, focus on addressing autoimmune and allergic diseases, respectively, and have shown differentiated preclinical profiles compared to existing therapies.

Dualitas serves a diverse client base within the biopharmaceutical industry, including potential partners in drug development and academic institutions focused on immunology and oncology. The primary geographical markets for Dualitas' products include North America, Europe, and select regions in Asia, where there is a growing demand for advanced therapeutic options in immune and inflammatory diseases. Dualitas Therapeutics' revenue model is anchored in strategic collaborations and partnerships with other biopharmaceutical companies and research institutions. The firm engages in B2B transactions, providing access to its DualScreen™ technology and pipeline programs, thus facilitating drug development partnerships.

Revenue is generated through structured agreements, including milestone payments tied to the progression of therapeutic candidates through clinical trials and potential royalties upon successful commercialization. The company’s flagship products, including DTX-102 and DTX-103, contribute to revenue streams as they advance towards regulatory approval and market entry. By focusing on differentiated pharmacology and innovative therapeutic mechanisms, Dualitas positions itself as a valuable partner in the evolving landscape of immunotherapy. In September 2025, Dualitas Therapeutics, Inc.

raised USD 65. 00 mn in venture funding to advance its research, develop new treatments, and expand its work into more immune-related diseases. The funding will support the design and launch of upcoming products, including further development of DTX-102 and DTX-103, targeting specific autoimmune and allergic conditions. Additionally, Dualitas plans to expand its operations into new markets, particularly in Europe and Asia, by 2025, in response to increasing demand for innovative therapeutic solutions.